Diabetes is a risk factor for colon, pancreas, breast, endometrium and liver cancer in women.
Peroxisome proliferator-activated receptors (PPARs) have emerged as important drug targets for diabetes. Drugs that activate PPARγ, such as the thiazolidinediones (TZDs), are widely used for treatment of Type 2 diabetes mellitus. PPARγ signaling could also play an anti-neoplastic role in several in vitro models, although conflicting results are reported from in vivo models. The effects of TZDs on cancer risk in humans needs to be resolved as these drugs are prescribed for long periods of time in patients with diabetes.
Actos is in the class of drugs known as TZDs or thiazolidinediones. TZDs are attractive options for the treatment of diabetes because they decrease insulin resistance.
It costs you nothing to call or to file a claim, our fees are based on any recovery.
Contact us toll free at (866) 200-2626 with your Actos® Bladder Cancer questions and to learn more about a possible Actos bladder cancer lawsuit.
In a multivariate logistic regression model, a diagnosis of cancer was significantly associated with TZD use, even after correcting for potential confounders including other oral anti-diabetic agents, age, glycosylated hemoglobin A1C, body mass index, cigarette smoking, high comorbidity, and number of prescription medications. This association was particularly strong among patients using rosiglitazone and among women.
Data suggest an association between TZD use and cancer in patients with diabetes.
Have you or a loved one suffered bladder cancer caused by the use of the TZD drug Actos? If the answer is yes – please contact Anapol Schwartz about filing a possible Actos bladder cancer lawsuit.
Source: BMC Medicine 2007, 5:17doi:10.1186/1741-7015-5-17